LaBrosse Nicole 4

What Happened Nicole LaBrosse, Chief Financial Officer of Halozyme Therapeutics (HALO), was credited on 2026-02-09 with a total of 42,117 restricted stock units (RSUs) awarded as performance-based stock units (PSUs). The three determinations (5,167; 7,448; and 29,502 units) are reported at $0.00 per unit (derivative awards) — this was an award/grant transaction (code A), not an open-market purchase or sale.

Key Details

• Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (period of report 2026-02-09).
• Units reported: 5,167; 7,448; and 29,502 — total 42,117 PSUs. Reported value per unit: $0.00 (derivative award).
• Shares owned after transaction: not disclosed in the filing.
• Footnotes summary:
  • The 5,167 units relate to a PSU grant dated Feb 16, 2023 with a performance period ending Dec 31, 2025; the number reflects the units that became eligible to vest based on that performance measure (F1).
  • The 7,448 units relate to a PSU grant dated Feb 23, 2024 with the same performance measurement period ending Dec 31, 2025 (F2).
  • The 29,502 units relate to a PSU grant dated Feb 20, 2025 with the same performance measurement period ending Dec 31, 2025 (F3).
  • Each unit is a contingent right to one share; all units remain subject to a service-based requirement through the third anniversary of their respective grant dates.

Context These are performance-based RSUs that the company has determined are eligible to vest based on the completed 2025 performance period — they are not yet issued shares and still require continued service until each grant’s third anniversary before actual delivery. This was an award/administrative determination rather than a market purchase or sale and should be viewed as a compensation/retention action rather than an immediate insider market move.